Literature DB >> 19078949

Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia.

Rose-Marie Karlsson1, Kohichi Tanaka, Lisa M Saksida, Timothy J Bussey, Markus Heilig, Andrew Holmes.   

Abstract

Glutamatergic dysfunction is increasingly implicated in the pathophysiology of schizophrenia. Current models postulate that dysfunction of glutamate and its receptors underlie many of the symptoms in this disease. However, the mechanisms involved are not well understood. Although elucidating the role for glutamate transporters in the disease has been limited by the absence of pharmacological tools that selectively target the transporter, we recently showed that glial glutamate and aspartate transporter (GLAST; excitatory amino-acid transporter 1) mutant mice exhibit abnormalities on behavioral measures thought to model the positive symptoms of schizophrenia, some of which were rescued by treatment with either haloperidol or the mGlu2/3 agonist, LY379268 the mGlu2/3 agonist, LY379268. To further determine the role of GLAST in schizophrenia-related behaviors we tested GLAST mutant mice on a series of behavioral paradigms associated with the negative (social withdrawal, anhedonia), sensorimotor gating (prepulse inhibition of startle), and executive/cognitive (discrimination learning, extinction) symptoms of schizophrenia. GLAST knockout (KO) mice showed poor nesting behavior and abnormal sociability, whereas KO and heterozygous (HET) both demonstrated lesser preference for a novel social stimulus compared to wild-type littermate controls. GLAST KO, but not HET, had a significantly reduced acoustic startle response, but no significant deficit in prepulse inhibition of startle. GLAST KO and HET showed normal sucrose preference. In an instrumental visual discrimination task, KO showed impaired learning. By contrast, acquisition and extinction of a simple instrumental response was normal. The mGlu2/3 agonist, LY379268, failed to rescue the discrimination impairment in KO mice. These findings demonstrate that gene deletion of GLAST produces select phenotypic abnormalities related to the negative and cognitive symptoms of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19078949      PMCID: PMC3400972          DOI: 10.1038/npp.2008.215

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  65 in total

1.  Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia.

Authors:  John H Krystal; Amit Anand; Bita Moghaddam
Journal:  Arch Gen Psychiatry       Date:  2002-07

2.  NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons.

Authors:  Houman Homayoun; Bita Moghaddam
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

Review 3.  Pharmacology and functions of metabotropic glutamate receptors.

Authors:  P J Conn; J P Pin
Journal:  Annu Rev Pharmacol Toxicol       Date:  1997       Impact factor: 13.820

Review 4.  Glutamate and schizophrenia: beyond the dopamine hypothesis.

Authors:  Joseph T Coyle
Journal:  Cell Mol Neurobiol       Date:  2006-06-14       Impact factor: 5.046

5.  Assessing nest building in mice.

Authors:  Robert M J Deacon
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

6.  Triple dissociation of anterior cingulate, posterior cingulate, and medial frontal cortices on visual discrimination tasks using a touchscreen testing procedure for the rat.

Authors:  T J Bussey; J L Muir; B J Everitt; T W Robbins
Journal:  Behav Neurosci       Date:  1997-10       Impact factor: 1.912

Review 7.  Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease.

Authors:  Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2008-03-26       Impact factor: 8.989

8.  NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex.

Authors:  Mark E Jackson; Houman Homayoun; Bita Moghaddam
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-24       Impact factor: 11.205

Review 9.  Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases.

Authors:  Paolo Gubellini; Antonio Pisani; Diego Centonze; Giorgio Bernardi; Paolo Calabresi
Journal:  Prog Neurobiol       Date:  2004-12       Impact factor: 11.685

10.  Impaired fear extinction learning and cortico-amygdala circuit abnormalities in a common genetic mouse strain.

Authors:  Kathryn Hefner; Nigel Whittle; Jaynann Juhasz; Maxine Norcross; Rose-Marie Karlsson; Lisa M Saksida; Timothy J Bussey; Nicolas Singewald; Andrew Holmes
Journal:  J Neurosci       Date:  2008-08-06       Impact factor: 6.167

View more
  85 in total

Review 1.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 2.  Translational potential of astrocytes in brain disorders.

Authors:  Alexei Verkhratsky; Luca Steardo; Vladimir Parpura; Vedrana Montana
Journal:  Prog Neurobiol       Date:  2015-09-16       Impact factor: 11.685

3.  Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex.

Authors:  Benjamin Kolisnyk; Mohammed A Al-Onaizi; Pedro H F Hirata; Monica S Guzman; Simona Nikolova; Shahar Barbash; Hermona Soreq; Robert Bartha; Marco A M Prado; Vania F Prado
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

4.  Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Authors:  Colm M P O'Tuathaigh; Brian P Kirby; Paula M Moran; John L Waddington
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

5.  Abnormal partitioning of hexokinase 1 suggests disruption of a glutamate transport protein complex in schizophrenia.

Authors:  Dan Shan; Daniel Mount; Stephen Moore; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2014-02-21       Impact factor: 4.939

6.  Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia.

Authors:  Parisa Afshari; Marina Myles-Worsley; Ori S Cohen; Josepha Tiobech; Stephen V Faraone; William Byerley; Frank A Middleton
Journal:  Mol Neuropsychiatry       Date:  2015-07-08

7.  A Glutamate Transporter EAAT1 Gene Variant Influences Amygdala Functional Connectivity in Bipolar Disorder.

Authors:  Sara Poletti; Martina Riberto; Benedetta Vai; Davide Ghiglino; Cristina Lorenzi; Alice Vitali; Silvia Brioschi; Clara Locatelli; Alessandro Serretti; Cristina Colombo; Francesco Benedetti
Journal:  J Mol Neurosci       Date:  2018-08-02       Impact factor: 3.444

Review 8.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

9.  Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia.

Authors:  Inna Gaisler-Salomon; Gretchen M Miller; Nao Chuhma; Sooyeon Lee; Hong Zhang; Farhad Ghoddoussi; Nicole Lewandowski; Stephen Fairhurst; Yvonne Wang; Agnès Conjard-Duplany; Justine Masson; Peter Balsam; René Hen; Ottavio Arancio; Matthew P Galloway; Holly M Moore; Scott A Small; Stephen Rayport
Journal:  Neuropsychopharmacology       Date:  2009-06-10       Impact factor: 7.853

Review 10.  Consideration of species differences in developing novel molecules as cognition enhancers.

Authors:  Jared W Young; J David Jentsch; Timothy J Bussey; Tanya L Wallace; Daniel M Hutcheson
Journal:  Neurosci Biobehav Rev       Date:  2012-10-12       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.